Companies in #Neuroscience

AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.

Clinical-stage neuroscience company developing treatments for substance use disorders and neurological conditions.

Biogen is a leading global biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes medicines for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and rare diseases, with a growing late-stage neurology pipeline and recent expansion into rare diseases through the Reata Pharmaceuticals acquisition.

Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and neuropsychiatric diseases. Following the spin-off of its commercial migraine portfolio to Pfizer, Biohaven is advancing next-generation neuroscience programs including IGF-1 targeted therapies and rare disease programs.

Clinical-stage biopharmaceutical company using AI to identify and develop novel therapies in neuroscience and immuno-oncology. Filed for bankruptcy in August 2026 and agreed to sell assets to Teva Pharmaceutical for up to $125M.

Global biopharmaceutical company (NYSE: BMY) focused on oncology, hematology, immunology, cardiovascular, neuroscience and fibrotic disease; marketed assets include Opdivo (nivolumab), Yervoy, Revlimid, Eliquis (apixaban with Pfizer), Pomalyst, Sprycel, Reblozyl, Sotyktu, deucravacitinib and the cardio-failure drug Camzyos; major acquisitions: Celgene ($74B, 2019), MyoKardia ($13B, 2020), Turning Point Therapeutics ($4.1B, 2022), Karuna Therapeutics ($14B, 2024), RayzeBio ($4.1B, 2024).

Digital therapeutics company developing prescription software treatments for neuropsychiatric and neurological conditions, including schizophrenia, major depressive disorder and migraine.

Global healthcare media and marketing agency specializing in pharmaceutical and life sciences brand strategy, media planning, and medical communications. A WPP company.

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology, and fibrotic disease. The company was incorporated in 2009 as Pipeline Therapeutics and renamed Contineum Therapeutics in November 2023 to reflect its expansion into fibrotic indications, and is based in San Diego, California. Its two clinical programs target de-risked mechanisms with existing human data: PIPE-791, an LPA1 receptor antagonist being developed in idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 muscarinic receptor antagonist licensed to Johnson & Johnson as JNJ-5120 and in development for major depressive disorder and remyelination in multiple sclerosis. Contineum listed on Nasdaq in April 2024 and carries a substantial cash balance relative to its operating burn, which leaves the equity sensitive to clinical readouts on its partnered and wholly owned programs rather than to near-term financing risk.

Japanese pharmaceutical company with a focus on neuroscience and oncology, known for developing the Alzheimer's treatment Leqembi (lecanemab) in partnership with Biogen.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

AI-driven small molecule drug discovery company whose Enchant platform combines generative models such as NeuralPLexer with high-throughput experimentation to design therapeutics; partnered with AbbVie and Revolution Medicines.

Machine-learning-driven drug discovery company that builds predictive models of human disease from large-scale cellular data and patient genetics, then advances the resulting insights into small-molecule and antibody therapeutics.

Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.

Clinical-stage biotech leveraging insights into neural signaling pathways to develop novel medicines for migraine and metabolic disorders, with a late-stage pipeline built on newly identified neural circuits.

Clinical-stage cell therapy company developing laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy, for hypoplastic left heart syndrome, Alzheimer's disease and aging frailty.

UK-based drug discovery and development company focused on selective mitophagy modulation through USP30 inhibition for CNS and kidney disease.

Clinical-stage genetic medicines company developing treatments for rare neurological diseases, led by NGN-401 gene therapy for Rett syndrome and a proprietary gene regulation platform.

Bresso, Italy-based CNS biopharmaceutical company developing evenamide, a glutamate modulator in Phase 3 for treatment-resistant schizophrenia, and marketing Xadago (safinamide) for Parkinson's disease.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Global CNS-focused biopharmaceutical company developing and commercialising treatments for epilepsy, sleep disorders and oncology, including cenobamate (XCOPRI/Ontozry).

Slate Medicines is a clinical-stage biotechnology company developing anti-PACAP therapeutics for migraine and headache disorders. The company launched in 2026 with a $130M Series A to advance its lead program SLTE-1009 and other PACAP-pathway candidates, joining a competitive class of next-generation migraine developers seeking to challenge the CGRP inhibitor standard of care.

Clinical-stage company developing AAV-based gene therapies for monogenic diseases of the central nervous system, with a lead program in Rett syndrome.

AI-driven drug discovery company applying generative models and machine learning to small molecule and biologics design.

Neurology-focused biopharmaceutical company applying its Extreme Genetics discovery platform to Kv7 and other ion-channel modulators, led by azetukalner for epilepsy and major depressive disorder.